For patients and doctors battling resistant infections, Validus Cellular Therapeutics is developing VCT-001, a novel preclinical stage anti-infective therapy unlike current small molecule antibiotics, which are susceptible to resistance and are limited accessing infections.
Bacterial Infections
09/092021
08/202021
Medical College of Wisconsin inventors have developed a novel biotherapeutic for eliminating antibiotic-resistant enterococci from the GI tract.
06/032021
Researchers at Kansas State University have developed a structure-based multiepitope fusion antigen (MEFA) technology for vaccines against Enterotoxigenic Escherichia coli (ETEC) bacteria.
04/092021
Researchers at the University of Missouri have developed novel inhibitors of beta-lactamase, a bacterial enzyme that provides resistance to β-lactam antibiotics.